Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 5/20 | 0.56 |
| ▸ | PLG | P00747 | 2/20 | 0.56 |
| ▸ | PLAT | P00750 | 2/20 | 0.56 |
| ▸ | BCL9 | O00512 | 12/20 | 0.53 |
| ▸ | CTNNB1 | P35222 | 12/20 | 0.53 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.50 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23970018 | 0.93 | PLAU (0.52) | PLAUPLGPLATBCL9CTNNB1 | |
| SCHEMBL24477136 | 0.92 | CTNNB1 (0.49) | PLAUPLGPLATBCL9CTNNB1 | |
| SCHEMBL23970099 | 0.92 | BCL9 (0.55) | PLAUPLATBCL9CTNNB1 | |
| SCHEMBL23970013 | 0.91 | BCL9 (0.54) | PLAUPLGPLATBCL9CTNNB1 | |
| SCHEMBL23969970 | 0.91 | PLAU (0.56) | PLAUPLGPLATBCL9CTNNB1 | |
| SCHEMBL23970069 | 0.91 | CTNNB1 (0.50) | PLAUPLATBCL9CTNNB1 | |
| SCHEMBL23969940 | 0.91 | PLAU (0.50) | PLAUPLGPLATBCL9CTNNB1 | |
| SCHEMBL23970020 | 0.91 | HSP90AA1 (0.49) | PLAUPLGPLATBCL9CTNNB1 | |
| SCHEMBL23969925 | 0.91 | CTNNB1 (0.48) | PLAUPLGPLATBCL9CTNNB1 | |
| SCHEMBL23970010 | 0.91 | BCL9 (0.64) | BCL9CTNNB1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022078470-A1 | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION | RANOK THERAPEUTICS (HANGZHOU) CO. LTD. (CN) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022078350-A1 | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION | RANOK THERAPEUTICS (HANGZHOU) CO. LTD. (CN) | 2022-04-21 | — | — | WO | disclosed |
| EP-3066072-B1 | BIPHENYLAMIDE DERIVATIVE HSP90 INHIBITORS | UNIV KANSAS (US) | 2021-11-03 | — | — | EP | disclosed |
| US-10689344-B2 | Biphenylamide derivative Hsp90 inhibitors | UNIVERSITY OF KANSAS (US) | 2020-06-23 | — | — | US | disclosed |
| US-20160272584-A1 | BIPHENYLAMIDE DERIVATIVE HSP90 INHIBITORS | UNIVERSITY OF KANSAS (US) | 2016-09-22 | — | — | US | disclosed |
| WO-2015070091-A1 | BIPHENYLAMIDE DERIVATIVE HSP90 INHIBITORS | THE UNIVERSITY OF KANSAS (US) | 2015-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10689344-B2 | Biphenylamide derivative Hsp90 inhibitors | HSP90AB1, HSP90AA1, HSP90AB2P | PLAU 4810/4885PLG 4537/4885PLAT 4154/4885 |
| US-20160272584-A1 | BIPHENYLAMIDE DERIVATIVE HSP90 INHIBITORS | HSP90AB1, HSP90AA1, HSP90AB2P | PLAU 4810/4885PLG 4537/4885PLAT 4154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.